Replies to post #417650 on Amarin Corp Plc (AMRN)

[ziploc_1]

jmcrr...Since the Brave study has already been concluded and the results are now being analyzed, I would surmise that the the announcement of the results will be made sometime before the end of the year.

The treatment group is rather small for statistical significance, so I don't expect that to be the case...but I do expect a positive trend for those patients in the study, who were taking Vascepa as opposed to those in the placebo group.

[Pharmacydude]

jfmcrr/zip

My best guess for presentation of BRAVE results:

Option 1:
Based on:
“A major event for Alzheimer’s disease research is the NIH Alzheimer’s Research Summit, which is organized by the National Institute on Aging every two years. The summit brings together experts from various disciplines and sectors to discuss the progress and challenges of the National Plan to Address Alzheimer’s Disease, which aims to effectively treat and prevent Alzheimer’s disease by 2025. The last summit was held on March 1-2, 2022 in Bethesda, Maryland”

So maybe in March 2024. Note: BRAVE funded by NIH so this seems the logical place to present trial results. Five months after trial completion is certainly enough time while not being an excessive delay (although we may feel differently)

Option 2:
Based on
“Alzheimer Society International Congress™ (ASIC 2024™)

ASIC 2024™ will be held on May 21-23, 2024 in San Francisco. ASIC 2024 is a leading forum in Alzheimer research and dementia care. The Congress will highlight the latest accomplishments in Alzheimer research and best practice in patient care.”

So maybe May 2024

They could also make an announcement next week - but I highly doubt that.

Vascepa has been available since 2012. A large insurance company like KP surely has enough Pt data over the past 11 years to do a statistical analysis of the prevalence of Alzheimer’s amongst V users vs similar pts who did not get V (a massive pool of these placebo pts)

[newman2021]

Holt